Pharmacological interventions for the prevention of fetal growth restriction: protocol for a systematic review and network meta-analysis by Bettiol, A. et al.
1Bettiol A, et al. BMJ Open 2019;9:e029467. doi:10.1136/bmjopen-2019-029467
Open access 
Pharmacological interventions for the 
prevention of fetal growth restriction: 
protocol for a systematic review and 
network meta-analysis
Alessandra Bettiol,1 Niccolò Lombardi,1 Giada Crescioli,1 Laura Avagliano,2 
Alessandro Mugelli,1 Claudia Ravaldi,3,4 Alfredo Vannacci  1,4
To cite: Bettiol A, 
Lombardi N, Crescioli G, et al.  
Pharmacological interventions 
for the prevention of fetal 
growth restriction: protocol for a 
systematic review and network 
meta-analysis. BMJ Open 
2019;9:e029467. doi:10.1136/
bmjopen-2019-029467
 ► Prepublication history and 
additional material for this 
paper are available online. To 
view these files, please visit 
the journal online (http:// dx. doi. 
org/ 10. 1136/ bmjopen- 2019- 
029467).
Received 28 January 2019
Revised 15 May 2019
Accepted 21 May 2019
1Department of Neurosciences, 
Psychology, Drug Research 
and Child Health, University of 
Florence, Florence, Italy
2Department of Health Sciences, 
San Paolo Hospital Medical 
School, Università degli Studi di 
Milano, Milano, Italy
3Department of Health Sciences, 
University of Florence, Florence, 
Italy
4CiaoLapo - Charity for Healthy 
Pregnancy, Stillbirth and 
Perinatal Loss Support, Prato, 
Italy
Correspondence to
Dr Alfredo Vannacci;  
 alfredo. vannacci@ unifi. it
Protocol
© Author(s) (or their 
employer(s)) 2019. Re-use 
permitted under CC BY-NC. No 
commercial re-use. See rights 
and permissions. Published by 
BMJ.
AbstrACt
Introduction Fetal growth restriction (FGR) includes 
different conditions in which a fetus fails to reach 
the own full growth, and accounts for 28%–45% of 
non-anomalous stillbirths. The management of FGR is 
based on the prolongation of pregnancy long enough 
for fetal organs to mature while preventing starvation. 
As for pharmacological management, most guidelines 
recommend treatment with low-dose aspirin and/or with 
heparin, although this approach is still controversial and 
innovative promising therapies are under investigation. 
As no firm evidence exists to guide clinicians towards 
the most effective therapeutic intervention, this protocol 
describes methods for a systematic review and network 
meta-analysis (NetMA) of pharmacological treatments for 
FGR prevention.
Methods and analysis We will search MEDLINE and 
Embase for clinical trials and observational studies 
performed on gestating women with clinically diagnosed 
risk of FGR. Experimental interventions will include heparin 
and low-molecular-weight heparin, acetylsalicylic acid, 
antiplatelet agents, phosphodiesterase type 3 and 5 
inhibitors, maternal vascular endothelial growth factor 
gene therapy, nanoparticles, microRNA, statins, nitric 
oxide donors, hydrogen sulphide, proton pump inhibitors, 
melatonin, creatine and N-acetylcysteine, and insulin-
like growth factors, compared between each other or to 
placebo or no treatment. Primary efficacy outcome is FGR. 
Secondary efficacy outcomes will be preterm birth, fetal or 
neonatal death and neonatal complications. For the safety 
outcome, all adverse events reported in included studies 
and experienced by either mothers, fetuses or newborns 
will be considered. Two review authors will independently 
screen title, abstract and full paper text, and will 
independently extract data from included studies. Where 
possible and appropriate, for primary and secondary 
efficacy outcomes, a NetMA will be performed using a 
random-effects model within a frequentist framework. 
Adverse events will be narratively described.
Ethics and dissemination Results will be disseminated 
through a peer-reviewed scientific journal, and by scientific 
congresses and meetings.
PrOsPErO registration number CRD42019122831.
IntrOduCtIOn
Fetal growth restriction (FGR), also known 
as intrauterine growth restriction, includes 
different conditions in which a fetus fails to 
reach its own growth potential. For many 
years, the most common parameter used 
to measure FGR was small for gestational 
age (SGA),1 although the two terms are not 
synonymous. Recently, an international clin-
ical consensus was obtained about the defi-
nition of FGR2; therefore, works aimed to 
study the risk of growth-related adverse fetal 
outcome should focus on true FGR. Namely, 
SGA is usually defined by a fetal size <10th 
centile for a population or customised stan-
dard.1 However, this definition includes also 
a proportion of constitutionally small but 
health fetuses while excluding a group of 
fetuses with biometry >10th percentile but 
not meeting their own growth potential. On 
the other hand, the concept of FGR applies 
only to non-healthy fetuses that failed to 
reach their growth potential and thus are at 
increased risk of adverse outcomes.2 
According to the definition identified 
through a Delphi consensus procedure,2 early 
FGR (ie, at gestational age <32 weeks), in the 
absence of congenital anomalies, is defined 
by fetal abdominal circumference (AC)/
estimated fetal weight (EFW) <3rd centile or 
umbilical artery (UA) absent end-diastolic 
strengths and limitations of this study
 ► Both clinical trials and observational studies will be 
included.
 ► Where possible, results will be synthetised using a 
network meta-analysis, thus allowing to simultane-
ously combine both direct and indirect evidence.
 ► The study team includes clinicians, pharmacologists 
and experts in the field of pregnancy complications 
and related therapeutic interventions.
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flow, or by the co-presence of AC (EFW <10th centile 
and uterine artery pulsatility index (PI) >95th centile, 
alone or in combination with UA-PI >95th centile. On the 
other hand, late FGR (ie, at gestational age of 32 weeks 
of more), is defined, in the absence of congenital anom-
alies, by AC/EFW <3rd centile or by the co-presence of at 
least two parameters among (i) AC/EFW <10th centile, 
(ii) AC/EFW crossing centiles >2 quartiles on growth 
centiles or (iii) cerebroplacental ratio <5th centile or 
UA-PI >95th centile.
Suboptimal fetal growth accounts for 28%–45% of cases 
of non-anomalous stillbirth.3 4
Causes of FGR can be fetus-related or mother-related: 
among the former, there are chromosomal anomalies, 
genetic syndromes and infections. Among maternal 
conditions, the most common are clinically relevant 
conditions such as autoimmune disorders, clinically rele-
vant conditions such as autoimmune disorders, hypox-
emic conditions (such as severe anaemia, congenital 
cyanotic heart diseases), cardiovascular diseases (such as 
hypertension) or the exposition to environmental toxins. 
The mechanism leading to FGR involves an abnormal 
trophoblast invasion of the maternal spiral arteries during 
pregnancy, which results in an incomplete remodelling of 
these vessels and in the persistence of a high-resistance 
and low-flow uteroplacental circulation, which on its 
turn determines and insufficient gaseous and nutrient 
exchange for optimal fetal growth.5
This results in a cascade of events, including reduced 
placental perfusion, imbalance in angiogenic factors, 
and in vascular endothelial growth factor (VEGF) 
and placental growth factor, and may lead to placen-
ta-mediated complications of pregnancy such as FGR, 
preeclampsia, placental abruption and late pregnancy 
loss.6 7
The management of FGR is based on the prolongation 
of pregnancy long enough for fetal organs to mature 
while avoiding irreversible fetus’ sufferance.8 As for phar-
macological management, most guidelines recommend 
treatment with low-dose aspirin—in preference by gesta-
tional week 16—for prevention of FGR,9–12 although 
this approach is not universally accepted.13 The use of 
heparin is also controversial: the Canadian guideline 
recommends that heparin should be offered in selected 
women,9 although recent evidence indicates that enoxa-
parin is not effective in preventing FGR in women with 
previous severe or early-onset FGR, or in those with 
thrombophilia, and can therefore not be recommended 
for this purpose.1 14 Furthermore, several other promising 
therapies are currently under investigation.1
To date, given that no firm evidence exists to guide clini-
cians towards the most effective therapeutic intervention, 
planned early birth is recommended and offered once a 
fetus reaches a viable gestational age and size. However, 
preterm birth is further associated with a consistent risk 
of morbidity and mortality.1
In light of the above-mentioned lack in knowledge, 
we aim to perform a systematic review and network 
meta-analysis (NetMA) of clinical trials and observational 
studies conducted on gestating women at diagnosed risk 
of FGR, with the primary objective of estimating the effect 
of different pharmacological treatments on the incidence 
of FGR.
Secondary efficacy objectives include the evaluation of 
the effect of different therapeutic strategies on the inci-
dence of (i) preterm birth; (ii) fetal or neonatal death 
and (iii) neonatal complications related to the abnormal 
growth. Safety objective includes the evaluation of adverse 
events involving treated women, fetuses or newborns.
MEthOds And AnAlysIs
This protocol has been written according to the Preferred 
Reporting Items for Systematic Review and Meta-Analysis 
Protocols guidance.15 
Eligibility criteria
Studies will be selected according to the eligibility criteria 
outlined below.
Study designs
We will consider for inclusion both clinical trials and 
observational cohort studies, either prospective or retro-
spective. Observational cross-sectional studies or case–
control studies will be excluded. Similarly, we will exclude 
reviews and meta-analyses, letters to the editor, case 
reports, case series and expert opinions.
Participants
We will include studies performed on gestating women at 
diagnosed risk of FGR, including16 the following:
 ► History of late pregnancy loss or FGR.
 ► History of recurrent pregnancy loss (define by three 
or more consecutive first trimester spontaneous 
abortions).
 ► Hypertensive diseases.
 ► Pre-eclampsia (in the current or previous 
pregnancies).
 ► Diabetes mellitus.
 ► Congenital cyanotic heart diseases.
 ► Restrictive pneumopathies.
 ► Severe renal diseases.
 ► Autoimmune diseases.
 ► Hereditary or acquired thrombophilia.
 ► Severe anaemia.
Other risk factors for FGR reported by the clinicians as 
present in the cohort of women in the retrieved studies 
will be evaluated case by case for possible inclusion.
No restriction on maternal age will be applied.
We will include only studies performed on women 
without or not carrying fetuses with congenital anoma-
lies, including abnormal karyotype and/or genetic anom-
alies, and malformations. We will also include only studies 
performed on women without intrauterine infections 
and/or without history of drug or alcohol abuse.
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No other restriction on maternal clinical conditions 
will be applied.
Interventions
Based on current experimental treatments for FGR,1 we 
will consider the following therapeutic interventions:
 ► Heparin or low-molecular-weight heparin.
 ► Acetylsalicylic acid.
 ► Other antiplatelet agents (including ditazole, cloric-
romen, clopidogrel, ticlopidine, dipyridamole, carba-
salate, epoprostenol, indobufen, iloprost, aloxiprin, 
eptifibatide, tirofiban, triflusal, beraprost, trepros-
tinil, prasugrel, cilostazol, ticagrelor, cangrelor, vora-
paxar and selexipag).
 ► Phosphodiesterase type 5 inhibitors.
 ► Phosphodiesterase type 3 inhibitors.




 ► Nitric oxide donors.
 ► Hydrogen sulfide.




 ► Insulin-like growth factor 1 and 2 (IGF1 and IGF2).
Studies in which patients were co-treated with more 
than one above-mentioned treatment will be included, as 
well.
Additional pharmacological interventions, not listed 
above and detected by screening of retrieved references 
or in the bibliographies of evaluated studies, will be 
further considered; if pertinent, search strategies will be 
updated and related references will be retrieved.
There will be no restriction in the pregnancy week of 
beginning of the therapeutic intervention.
Comparators
We will consider studies comparing the effect of the 
above-mentioned interventions versus placebo or no 
treatment (considered together), or versus active control, 
that is, a second treatment listed above.
Outcomes
We will include only studies evaluating the primary effi-
cacy outcome, that is, FGR. As the definition of FGR is 
based on biometric measures not always reported in 
details in published studies, we will accept the diagnosis 
of FGR provided by the authors of the studies.
In studies evaluating the above-mentioned primary 
outcome, also the following secondary efficacy outcomes 
will be considered (when reported):
 ► Preterm birth, defined as a delivery before completing 
37 weeks of gestation.
 ► Fetal or neonatal death, including the events related 
to early or late pregnancy loss, and perinatal and early 
neonatal death.17
 ► Neonatal complications, including necrotising enter-
ocolitis, respiratory distress syndrome, bronchopul-
monary dysplasia, intraventricular haemorrhage, 
retinopathy of prematurity, periventricular leucoma-
lakia and other conditions related to the abnormal 
growth and reported in the considered studies.
In studies reporting the primary outcome, also data 
related to placental lesions (ie, fetal and maternal vascular 
malperfusion) will be retrieved.18
As for safety outcomes, we will consider any side effect 
experienced by treated women or by fetuses or newborns 
in included studies; side effects will be defined based on 
authors’ definitions.
In addition, in studies reporting the primary outcome, 
all maternal adverse events (such as pre-eclampsia, 
placental abruption, etc) will be evaluated.
Timing
There will be no timing restriction.
Setting
There will be no restriction by type of setting.
Language
We will include only articles written in the English 
language.
Information sources and search strategy
Electronic searches will be performed in the databases 
MEDLINE and Embase.
The MEDLINE search strategy is reported in online 
supplementary material 1.
The MEDLINE search strategy will be adapted to the 
syntax and subject headings of the Embase.
Records will be retrieved on the same day from all 
sources.
The search strategy will be updated towards the 
end of the review, after being validated to ensure that 
the MEDLINE strategy retrieves a high proportion of 




Retrieved records will be managed using the software 
Endnote.
Selection process
Two review authors will independently screen the 
extracted records. The two review authors will inde-
pendently identify studies for inclusion by screening 
titles and abstracts yielded by search, eliminating those 
deemed irrelevant. We will retrieve full-text articles for 
all references that at least one of the review authors will 
identify for potential inclusion. We will select studies for 
inclusion on the basis of review of full-text articles. We will 
resolve discrepancies through discussion.
Neither of the review authors will be blind to the journal 
titles or to the study authors or institutions.
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Data collection
Two review authors will independently extract data from 
the included studies.
Data abstracted will include demographic information, 
methodology, intervention details, all reported clinically 
relevant conditions and outcomes. Data will be extracted 
at the trial arm level, rather than the individual patient 
level. We will resolve discrepancies between authors 
through discussion.
data items
Extracted data will include the name of the study authors 
and year of publication, the study design and character-
istics (including single or double blinding and randomis-
ation), the country in which participants were recruited, 
and eventual funding sources.
As for the population, we will extract the women’s age, 
the specific risk factors for FGR and other clinically rele-
vant comorbidities.
As for the intervention and the comparator, we will 
extract the active principle of the experimental interven-
tion, its route of administration, the treatment dosage, 
the gestation week at time of treatment beginning and 
the duration of treatment.
We will extract the number of randomised participants, 
the number of participants included in the analysis, the 
number of participants with events for binary outcomes 
and the reported definition of outcomes, if appropriate. 
Whenever possible, we will use results from an intention-
to-treat analysis.
Outcomes and prioritisation
The primary outcomes will be the number of women 
experiencing FGR out of the total number of treated 
patients.
The secondary outcomes will be the number of cases of 
preterm birth and of fetal or neonatal death, out of the 
total number of treated patients. For neonatal compli-
cations, we will consider the number of newborns with 
a given complication out of the total number of treated 
cases.
For efficacy outcomes, where Odds Ratio (ORs) or 
relative risks and related Confidence Intervals (CIs) are 
reported, these will be transformed to absolute numbers.
Placental characteristics will be considered out of the 
total number of cases for whom placental evaluation was 
available, focusing on villous branching abnormalities 
and maternal decidual arteriopathy.
Safety outcomes will be the number of patients (either 
mothers, fetuses or newborns) experiencing any adverse 
event out of the total number of treated patients. Adverse 
events will be identified based on specific authors’ defi-
nitions, and will be classified using the Medical Dictio-
nary for Regulatory Activities (MedDRA)  classification, 
according to preferred terms and system organ class 
classification.19 Similarly, maternal adverse events (such 
as pre-eclampsia, placental abruption, etc) will be the 
number of women experiencing any event out of the total 
number of treated patients.
risk of bias
Two review authors will independently assess the included 
studies for bias. To assess the risk of bias of included 
randomised controlled trials, we will follow the Cochrane 
Handbook for Systematic Reviews of Interventions.20 
Specifically, we will assess the risk of bias in included trials 
for the following domains: selection (random sequence 
generation; allocation concealment); performance 
(blinding of participants and personnel); detection 
(blinding of outcome); attrition (incomplete outcome 
data); reporting (selective reporting); other unclear bias.
To assess the risk of bias of observational studies, we will 
follow the Newcastle-Ottawa Quality Assessment Scale.21 
Specifically, for included cohort studies, we will consider 
the following domains: selection (representativeness of 
the exposed cohort; selection of the non-exposed cohort; 
ascertainment of exposure; absence of outcome of interest 
at start of study); comparability; outcome (assessment of 
outcome; appropriate length of follow-up; adequacy of 
follow-up of cohorts).
For each domain in the two tools, we will describe 
the procedures undertaken for each study, including 
verbatim quotes. A judgement as to the possible risk of 
bias on each domain will be made from the extracted 
information, rating from ‘low risk’ to ‘high risk’.
The judgements will be made independently by two 
review authors; disagreement will be resolved first by 
discussion and then by consulting a third author.
We will compute graphic representations of potential 
bias within included studies, using the software RevMan 
V.5.3 (Review Manager 5.3).
data synthesis
If studies are sufficiently homogeneous in terms of design 
and comparator, we will synthesise results using a NetMA, 
thus allowing to simultaneously combine evidence from 
both direct head-to-head comparisons and indirect 
evidence, that is, interventions compared through a 
common comparator.22 23
Measures of treatment effect
All considered outcomes are based on dichotomous data. 
For all considered efficacy outcomes, we will perform a 
NetMA using a random-effects model within a frequen-
tist framework. We will calculate pooled ORs combining 
the estimates reported in each study using random-effects 
Mantel-Haenszel method.
For safety outcomes, no quantitative synthesis will 
be performed, and the proportions of each reported 
adverse event will be described at study level. Similarly, all 
reported maternal adverse events will be described, and 
no quantitative analysis will be performed.
For placental lesions, data from included studies 
will be narratively synthetised according to the type of 
described lesions (lesions related to maternal vascular 
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underperfusion versus fetal vascular underperfusion), 
and no quantitative analysis will be performed.
Unit of analysis issues
All analysis will be conducted per trial arm, rather than at 
individual patient level.
Dealing with missing data
When there are missing data, we will attempt to contact 
original study authors to obtain the relevant missing 
information. Important numerical data will be carefully 
evaluated. If missing data cannot be obtained, the study 
will be excluded from the related analysis.
Assessment of heterogeneity
We will evaluate the clinical heterogeneity by considering 
the variability in participants’ features among studies 
and in study characteristics (study design, intervention, 
follow-up).
We will evaluate statistical heterogeneity across studies 
using the I-squared and Cochran’s Q tests, and publica-
tion bias using plots of SE against effect estimate (bias is 
likely to cause asymmetry in such plots), or using formal 
tests such as Egger one or similar.
If high levels of heterogeneity exist (I-squared ≥50% or 
p<0.1), we will try to explain the source of heterogeneity 
by conducting subgroup or sensitivity analysis.
subgroup and sensitivity analyses
Subgroup analysis will be conducted for timing of inter-
vention (within vs after the first trimester of pregnancy). 
Additional subgroup analysis will be performed, if appro-
priate, according to the clinical characteristics of patients 
in included studies.
We will conduct a sensitivity analysis including only clin-
ical trials versus only observational studies. If possible, a 
second sensitivity analysis will be performed including 
only high-quality clinical trials.
Meta-biases
To determine whether reporting bias is present in 
included clinical trials, we will evaluate whether the 
protocol of the clinical trial was published before recruit-
ment of study patients. Specifically, for studies published 
after July 2005, we will screen the Clinical Trial Register 
at  ClinicalTrials. gov. We will evaluate whether selective 
reporting of outcomes is present (outcome reporting 
bias). The potential for reporting bias will be evaluated 
using funnel plots (if ≥10 studies are present).
Confidence in cumulative estimate
The quality of evidence will be judged using the Grading 
of Recommendations Assessment, Development and Eval-
uation working group scale, considering the domains of 
risk of bias, consistency, directness, precision and publica-
tion bias. Quality will be adjudicated as high, moderate, 
low or very low.20
PAtIEnt  And PublIC InvOlvEMEnt
The project for this systematic review and NetMA was 
conceived within the frame of the CiaoLapo Onlus—a 
charity for support to stillbirth and perinatal loss in 
response to an unmet need suggested by healthcare 
professionals and patients.
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